PT Kalbe Farma TbkFRA:LCLA +1.52%77 Gross Margin % is 37.85% as of Mar. 2026, which is 12% below its 10-year median of 42.91. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 935 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks worse than 67.38% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
PT Kalbe Farma Tbk had a gross margin of 37.85% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
PT Kalbe Farma Tbk Gross Margin % Related Terms
PT Kalbe Farma Tbk Gross Margin % Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LCLA vs LLY, JNJ, ABBV: Gross Margin % Comparison
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's Gross Margin % distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
PT Kalbe Farma Tbk (FRA:LCLA) has a Gross Margin % of 37.85% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on PT Kalbe Farma Tbk and its competitors. This is 12% below median its historical median of 42.91. Over the past decade, PT Kalbe Farma Tbk's Gross Margin % has ranged from 38.21 to 48.97. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #630 out of 935 companies in the Drug Manufacturers industry, placing it in the top 67.4%.
Is PT Kalbe Farma Tbk's Gross Margin % too high?
PT Kalbe Farma Tbk's current Gross Margin % of 37.85% is 12% below median its 10-year median of 42.91. Over the past 10 years, this metric has ranged from a low of 38.21 to a high of 48.97. The Drug Manufacturers industry median Gross Margin % is 48.54. PT Kalbe Farma Tbk's value of 37.85% is 22% below this industry median. Based on the distribution chart, PT Kalbe Farma Tbk ranks #630 out of 935 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's Gross Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #630 out of 935 companies for Gross Margin %. This places PT Kalbe Farma Tbk in the lower half of its industry. The industry median Gross Margin % is 48.54. PT Kalbe Farma Tbk's value of 37.85% is 22% below this benchmark. Historically, PT Kalbe Farma Tbk's own Gross Margin % has ranged from 38.21 to 48.97 over the past decade. While the company's 10-year median is 42.91 vs. the industry median of 48.54, PT Kalbe Farma Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kalbe Farma Tbk's current Gross Margin % of 37.85% is 22% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on PT Kalbe Farma Tbk and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current Gross Margin % is 37.85%, which is 12% below median its own 10-year median of 42.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.07, compared to a current price of €0.03 — trading 52.1% below its estimated fair value. The current Gross Margin % is 37.85%, which is 12% below median its 10-year median of 42.91 and 22% below the Drug Manufacturers industry median of 48.54. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current Gross Margin % is 37.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.03 is trading 52.1% below its estimated GF Value™ of €0.07.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
Gross Margin %: 37.85% (12% below median its 10-year median of 42.91)
GF Value™: €0.07 vs. price of €0.03 (52.1% below fair value)
Industry Position: 22% below the Drug Manufacturers median (#630 of 935)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
